LTS takes another step in its growth journey with the acquisition of Tapemark Inc.


ANDERNACH, Germany, August 22, 2022 /PRNewswire/ — LTS LOHMANN Therapie-Systeme AG (“LTS”) announces the closing of the acquisition of Tapemark Inc. (“Tapemark”) located in St. Paul, MN, UNITED STATES. This acquisition combines Tapemark, a world-class CDMO specializing in transdermal drug delivery systems and oral thin films as well as unit dose semi-solid drugs and iontophoresis products with LTS, a pharmaceutical technology company from leading developer and manufacturer of innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Microarray Patches (MAP) for leading bio/pharmaceutical, generic and consumer health.

With the acquisition, Tapemark’s St. Paul the facility will be part of LTS’ global operating network, along with LTS’s existing facilities in Andernach, Germany and West Caldwell, New Jersey in the USA.

Bas van Buijtenen, CEO of LTS, said, “We are very excited to welcome the Tapemark team to the LTS family. This strategic acquisition demonstrates our commitment to continue setting the standard as the best CDMO in TTS and OTF and to strengthen our footprint. in the United States, the largest pharmaceutical market in the world. We will offer our customers and their patients an even more comprehensive portfolio of drug delivery expertise and expanded manufacturing capabilities, and we are excited to welcome Tapemark customers to the LTS global network. strengthens our R&D capabilities in North America, allowing us to provide ever more innovation and development support to players developing innovative therapies and new drug delivery systems. Thanks to this, we are even better placed to respond to our customers’ desire to have a single partner to accompany them from feasibility to commercialization.

We are particularly pleased to have such a talented team join our organization. I’m glad that Handsome Garrett will strengthen our global leadership team in the role of SVP Strategy and Corporate Development. His track record as a leader who has successfully driven growth will strengthen our LTS growth journey.”

Handsome GarrettTapemark CEO, said, “Joining LTS strengthens our ability to craft the best product development and manufacturing strategy to deliver complex medicines to our customers who ultimately bring them to market and help patients around the world. whole world. After talking to our customers, I know they are thrilled to benefit from the breadth of LTS’s global technology portfolio, product development capabilities, and extensive global network. Together we will reach more pharmaceutical partners and ultimately help more patients. Personally, I’m thrilled that our leadership team is joining such a strong team at LTS. From the day I met Bas and several of LTS’s top executives, I knew this was the right fit for both companies, our employees and our customers.

The transaction received the necessary regulatory approvals and closed on August 19, 2022. Financial details of the transaction are not disclosed. Bourne Partners acted as exclusive financial advisor to Tapemark.

About LTS:

LTS LOHMANN Therapie-Systeme AG is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as transdermal patches (“TTS”) and oral thin films (“OTF”) for the pharmaceutical industry. LTS maintains its leadership position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array (MAP) patches for transdermal delivery of large molecules, d biological assets and vaccines. Founded in 1984, LTS operates today from three sites: in Andernach, Germany, West Caldwell, New JerseyUnited States and St. Paul, MN, UNITED STATES. LTS also has a representative office in Shanghai, China.

Contact: dr. Iris Schnitzler
Call: +49 (0) 2632 99 – 2589
E-mail: [email protected]

SOURCE LTS Lohmann Therapie-Systeme AG


Comments are closed.